CD19 recombinant proteins and antibodies

CD19 is a transmembrane glycoprotein widely expressed on B cells, playing a pivotal role in B cell development and function. It serves as a key regulator in B cell activation, proliferation, and differentiation, making it an ideal target for immunotherapy in B cell-related diseases. Current drug development efforts targeting CD19 mainly focus on monoclonal antibodies, bispecific antibodies, and CAR-T cell therapies.

Among monoclonal antibodies, blinatumomab, a bispecific T-cell engager, simultaneously binds CD19 on B cells and CD3 on T cells, promoting T-cell-mediated cytotoxicity against tumor cells. Other anti-CD19 antibodies, such as Tafasitamab and loncastuximab tesirine, have demonstrated favorable efficacy and safety in clinical trials. CAR-T therapy represents a major advancement in CD19-targeted treatment. By genetically engineering a patient’s T cells to express a CD19-specific chimeric antigen receptor (CAR), CAR-T cells can efficiently recognize and eliminate B cell malignancies. This approach has also shown potential in treating autoimmune disorders. Emerging strategies, such as in vivo delivery of CAR genes via lipid nanoparticles, aim to simplify the production process, reduce costs, and improve therapy accessibility.

Overall, CD19-targeted therapies exhibit significant promise in treating B cell-related diseases. Ongoing research is focused on enhancing efficacy, minimizing adverse effects, and improving the convenience and accessibility of treatment, providing patients with safer and more effective therapeutic options.

To assist in the development of CD19 targeted therapies, DIMA BIOTECH can now provide a full range of products and services for CD19 target. Products include active CD19 recombinant proteins, full-length CD19 proteins, CD19 reference antibodies, and FC-verified monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of CD19 biotherapy, DIMA BIOTECH has also prepared a CD19 target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple CD19 IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.